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Distinct genetic architectures and environmental
factors associate with host response to the
γ2-herpesvirus infections
Neneh Sallah 1,2,14✉, Wendell Miley3, Nazzarena Labo3, Tommy Carstensen1,4, Segun Fatumo1,2,5,
Deepti Gurdasani1,6, Martin O. Pollard 1,4, Alexander T. Dilthey 7, Alexander J. Mentzer 8,9,
Vickie Marshall3, Elena M. Cornejo Castro 3, Cristina Pomilla1,4, Elizabeth H. Young1,4, Gershim Asiki 10,
Martin L. Hibberd 2, Manjinder Sandhu 4, Paul Kellam 11,12, Robert Newton5,16, Denise Whitby3,16 &
Inês Barroso 1,13,15,16✉
Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein-Barr Virus (EBV) establish life-
long infections and are associated with malignancies. Striking geographic variation in inci-
dence and the fact that virus alone is insufficient to cause disease, suggests other co-factors
are involved. Here we present epidemiological analysis and genome-wide association study
(GWAS) in 4365 individuals from an African population cohort, to assess the influence of
host genetic and non-genetic factors on virus antibody responses. EBV/KSHV co-infection
(OR= 5.71(1.58–7.12)), HIV positivity (OR= 2.22(1.32–3.73)) and living in a more rural area
(OR= 1.38(1.01–1.89)) are strongly associated with immunogenicity. GWAS reveals asso-
ciations with KSHV antibody response in the HLA-B/C region (p= 6.64 × 10−09). For EBV,
associations are identified for VCA (rs71542439, p= 1.15 × 10−12). Human leucocyte antigen
(HLA) and trans-ancestry fine-mapping substantiate that distinct variants in HLA-DQA1
(p= 5.24 × 10−44) are driving associations for EBNA-1 in Africa. This study highlights
complex interactions between KSHV and EBV, in addition to distinct genetic architectures
resulting in important differences in pathogenesis and transmission.
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The gamma-herpesviruses, Epstein−Barr Virus (EBV) andKaposi sarcoma-associated herpesvirus (KSHV) are onco-genic viruses associated with several malignancies,
including >95% of Burkitt’s Lymphoma (BL) in parts of sub-
Saharan Africa and 100% of cases of Kaposi’s Sarcoma (KS),
respectively1,2. While EBV is ubiquitous globally, the prevalence
of, and deaths caused by several associated malignancies, display
extensive geographic variation. In contrast, KSHV displays
striking geographic variation that parallels associated KS inci-
dence, with highest prevalence reported in sub-Saharan Africa1,3.
The inter and intra-continental heterogeneity in the prevalence of
KSHV and incidence of associated malignancies, while attribu-
table to a number of factors including differences in pathogen
prevalence, may also be influenced by many environmental
determinants, host genetics and gene−environment interactions
in different populations. Synergistic and antagonistic interactions
have been reported for KSHV−EBV co-infection; B-lymphocytes
act as a reservoir of latent infection, in dually infected cells, both
viruses subvert the host immune response and inhibit lytic
reactivation of each other4–8. While viral genetic factors have
been extensively studied9,10, host genetic factors and their inter-
actions with the environment, leading to potential disease out-
comes, are largely unknown and require investigation,
particularly in Africa.
We and others have reported associations in the HLA class II
region with EBV EBNA-1 antibody response11–14. On the other
hand, host genetic studies for KSHV are lacking, with no genome-
wide association study (GWAS) performed for traits associated
with infection or diseases. The strong correlation of serological
status between siblings (not explained by known risk factors), and
the familial clustering of KSHV disease15–19 are all highly sugges-
tive of host genetic influence in addition to shared environmental
risk factors. Candidate gene, whole-exome and next-generation
sequencing methods have suggested Mendelian causes of rare
paediatric KS cases as a result of inborn errors in immunity.
However, the role of genetic variants in adult KS and in the viral
control in asymptomatic individuals is less clear20. To date, most
studies provided marginal evidence using statistically lenient p
value thresholds of between 0.01 and 0.05, which failed to correct
for multiple testing to declare “association” for variants in immu-
nomodulatory genes with virus biological function, pathogenesis
and tumourigenesis21–24. In addition, they had other limitations
including, very small sample sizes (between 1 and 350 cases), failure
to adjust for environmental factors such as co-infection with other
pathogens, or confounding by strong HLA associations with HIV
and AIDS, and did not stratify controls by KSHV serostatus or
include KSHV seronegative controls for comparison, and all lack
replication in independent samples. Lastly, only two studies23,25
have been conducted in African populations.
To overcome the limitations of previous studies and attempt to
identify convincing associations with KSHV and EBV immune
response traits, we assess systematic differences in >4000 indivi-
duals from an African population cohort, where both viruses are
endemic, using socio-demographic and clinical data to assess
intrinsic and environmental determinants of infection and then
perform a GWAS using antibody responses as markers of infec-
tion. We use whole-genome sequence data, dense genotyping
array data and imputation to a panel with African sequence data
to identify genetic loci associated with both infections and
attempt to replicate previously identified genetic loci in the
context of the environment.
Results
Characteristics of samples in the Uganda General Population
Cohort (GPC). To investigate the seroprevalence of infections, we
tested serum samples from 4365 individuals in the General
Population Cohort (GPC) collected during medical survey round
22 (in 2011). The GPC is a population-based cohort in Kyamu-
libwa, rural south-west Uganda, comprising inhabitants of 25
neighbouring villages26. Participants were over the age of 13 years
and belonged mainly (>70%) to the Baganda ethnolinguistic
group. Villages were categorised according to urbanicity quartiles
reflecting shared ‘urban’ characteristics based on differences in
economic activity, civil infrastructure, and availability of educa-
tional and healthcare services as previously described27, with 28%
living in quartile 1 (very rural i.e. no educational facilities and no
households with electricity) (Table 1). In this study, 91% of
individuals were categorised as seropositive for EBV based on
detectable IgG levels against either EBNA-1 or VCA28 and 91%
categorised as seropositive for KSHV based on detectable IgG
levels against either ORF73, K10.5 or K8.1 29,30 (Table 1). HIV
infection seroprevalence in this study was 6.5%, Hepatitis C virus
(HCV) seroprevalence was 3.7% and Hepatitis B virus (HBV)
infection had the lowest seroprevalence among the pathogens
examined at 2.9% (Table 1). Nearly 95% of participants, 4134
individuals, were infected with at least one of these viruses. The
majority of participants, 2743 (63%) were seropositive to at least
two of the viruses tested, 23 (0.5%) participants were seropositive
for four viruses and 231 (5.3%) participants were seronegative for
all viruses (Supplementary Fig. 1). Co-infection with KSHV and
EBV was the most common with >95% of dually infected indi-
viduals (Supplementary Table 1.). Co-infections of other patho-
gens with EBV or KSHV was similarly frequent and mirrored the
seroprevalence estimates seen in the cohort (Supplementary
Table 1).
Table 1 Characteristics of individuals in the GPC.
Characteristic N= 4365 (%)
Sex
Female 2537 58.1
Male 1828 41.9
Age group (year)
13−18 1078 24.7
19−39 1828 41.9
40+ 1459 33.4
Ethnic group
Baganda 3328 76.2
Other 1037 23.8
Education level attained
Primary 1538 35.2
Junior secondary 1460 33.4
Senior secondary 905 20.7
Tertiary 223 5.1
Urbanicity quartile
1 1222 28.0
2 982 22.5
3 953 21.8
4 963 22.1
KSHV
Positive 3988 91.3
EBV
Positive 3956 90.6
HIV
Positive 284 6.5
Hepatitis B
Positive 126 2.9
Hepatitis C
Positive 161 3.7
N the number of unique individuals.
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To investigate the inter-individual variation of IgG antibody
responses marking different stages of the viral life cycles (latent vs
lytic) to KSHV and EBV infections, distributions of antibody
levels were determined to the latent (ORF73, K10.5, EBNA-1) and
lytic antigens (K8.1, VCA and EAD) in 4365 individuals. All
antibody responses were highly variable across individuals as
shown by the wide range of median fluorescent intensity (MFI)
(Fig. 1a). For KSHV, seropositivity to the K8.1 and ORF73 were
both high >80% with similar distributions observed for all anti-
KSHV IgG (Fig. 1a). For EBV, seropositivity to EBNA-1 was
highest at 83% (Fig. 1b) with the lowest antibody responses
observed for EAD (Fig. 1b). The IgG responses were modestly
phenotypically correlated (r2: 0.1−0.43) (Supplementary Fig. 2).
Environmental determinants of KSHV IgG antibody response.
To assess the contribution of environmental determinants on
KSHV serostatus (i.e. seropositive vs seronegative) and specific
IgG antibody response levels [MFI], we investigated 4365 indi-
viduals from the GPC26. We selected age, sex, socio-demographic
and infection status factors (Table 1) that could potentially
influence serostatus or the levels of seroreactivity to KSHV
antigens. Following a multivariate logistic regression analysis,
being EBV positive had the largest effect on KSHV serostatus
(OR= 5.68, 95% CI= 4.55−7.06), and being male (OR= 1.35,
95% CI= 1.17−1.57) was also significantly associated with ser-
opositivity (Fig. 2a). Living in a lower urbanicity quartile, lower
educational attainment and HIV negativity were also significantly
associated with seropositivity in individuals albeit with modest
effect sizes (Fig. 2a and Supplementary Data 1). We further
assessed the contribution of the same factors on IgG antibody
levels to all antigens using a multivariate linear regression ana-
lysis. Similar to serostatus, anti-KSHV IgG levels were sig-
nificantly higher in EBV seropositive individuals (OR= 2.19, 95%
CI= 1.88−2.22) and higher in males than in females, particularly,
for anti-ORF73 (OR= 1.17, 95% CI= 0.08−0.148) (Fig. 2b and
Supplementary Data 1). HIV seropositivity was significantly
associated with decreased IgG antibody levels (OR= 0.86, 95%
CI= 0.73–0.93), as were higher education levels, particularly
tertiary education attainment (OR= 0.84, 95% CI= 0.72–0.92)
(Fig. 2b). Age, ethnolinguistic group, HBV and HCV co-
infections had no significant associations with KSHV serostatus
or antibody levels. Full association results can be found in Sup-
plementary Data 1.
Environmental determinants of EBV IgG antibody response.
We then assessed the contribution of environmental determi-
nants (Table 1) on EBV serostatus (i.e. seropositive vs ser-
onegative) and the levels of EBV antigen-specific IgG antibodies.
KSHV seropositivity (OR= 5.71, 95% CI= 4.58−7.12) had the
largest effect on EBV serostatus (Fig. 3a). Living in an urbanicity
quartile of 3 (OR= 1.38, 95% CI= 1.01−1.89) and HIV infection
(OR= 2.22, 95% CI= 1.32−3.73) were also significantly asso-
ciated with seropositivity to EBV (Fig. 3a and Supplementary
Data 2). Unlike KSHV, sex, or education level were not sig-
nificantly associated with EBV serostatus (Supplementary
Data 2). KSHV seropositivity was also significantly associated
with lower IgG antibody levels for all EBV antigens (Fig. 3b and
Supplementary Data 2). HIV seropositivity was associated with
higher antibody levels to lytic antigens VCA and EAD (OR=
1.37, 95% CI= 1.27−1.47) but not the latent antigen EBNA-1.
Living in a higher urbanicity quartile of 3 was also associated
with increased antibody levels to EBNA-1 (OR= 1.11, 95% CI=
1.05−1.18) but not the lytic antigens (Fig. 3b and Supplementary
Data 2). Anti-EAD was the only antibody that decreased with
living in an urbanicity quartile of 4 (OR= 0.88, 95% CI=
0.85−0.91) (Fig. 3b and Supplementary Data 2). Ethnicity, edu-
cation level and HCV co-infection had no significant influence on
IgG levels (Supplementary Data 2).
Genetic determinants of anti-KSHV and anti-EBV antibody
responses. To assess the contribution of human genetic variation
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Fig. 1 Inter-individual variability in IgG antibody responses to KSHV and EBV (n= 4365 individuals). a Distribution of anti-KSHV antibody levels (Log10
MFI) for K10.5 (min= 0, max= 28,514), K8.1 (min= 0, max= 26,468) and ORF73 (min= 0, max= 29,308). b Distribution of anti-EBV antibody levels
(Log10 MFI) for EAD (min= 0, max= 22,747), EBNA-1 (min= 0, max= 24,696), VCA (min= 11, max= 24,754). Seropositivity to all antigens and median
(centre) plus IQR displayed in the text box.
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Fig. 2 Predictors of KSHV IgG antibody response. Odds ratios (ORs) and 95% confidence intervals (CI) of significant associations (p < 0.006) between
factors and IgG variable as determined based on serologies in the 4365 individuals from the GPC. a Predictors of IgG serostatus. ORs and 95% CI were
estimated following a multivariate logistic regression analysis with serostatus (seropositive vs seronegative) as response variable. b Predictors of IgG
response level. ORs and 95% CI were estimated following a multivariate linear regression analysis with log10-transformed MFI as response variable. UQ
urbanicity quartile. Dots represent the ORs and are coloured by IgG variable: KSHV (seropositivity to any antigen)—purple, ORF73—red, K8.1—yellow,
K10.5—light blue; lines represent the 95% confidence intervals. Full results from this analysis are provided in Supplementary Data 1.
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on antibody responses to KSHV (N= 4365) and EBV (N=
4365), we first explored the heritability of anti-KSHV and anti-
EBV IgG serological traits in the GPC. As most individuals in the
cohort are seropositive (>90%) presumably from childhood30,
those who present as seronegative are also likely to have been
infected and thus, produced antibodies at very low/undetectable
levels; as such, they are also informative and useful to include in
analysis. In this study, heritability estimates were high for anti-
ORF73 (h2= 33%, 95% CI= 24–42%), anti-K8.1 (h2= 25%, 95%
CI= 16–35%) and anti-K10.5 (h2= 32%, 95% CI= 23–41%),
and for anti-EBNA-1 (h2= 36%, 95% CI= 28–45%) and anti-
VCA IgG (h2= 32%, 95% CI= 23–41%). After correction for
unmeasured shared environmental correlation, accounted for by
GPS coordinates11,31, our estimates were reduced yet still
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Fig. 3 Predictors of EBV IgG antibody response. Odds ratios (ORs) and 95% confidence intervals (CI) of significant associations (p < 0.006) between
factors and IgG variable as determined based on serologies in the 4365 individuals from the GPC. a Predictors of IgG serostatus. ORs and 95% CI were
estimated following a multivariable logistic regression analysis with serostatus (seropositive vs seronegative) as response variable. b Predictors of IgG
response level. ORs and 95% CI were estimated following a multivariable linear regression analysis with log10-transformed MFI levels as response variable.
UQ urbanicity quartile. Dots represent the ORs and are coloured by IgG variable (EBV (seropositivity to EBNA-1 or VCA)—blue, EBNA-1—magenta, VCA—
light green, EAD—orange), lines represent the 95% confidence intervals. Full results from this analysis are provided in Supplementary Data 2.
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significant for all traits as previously found in our pilot study11,
anti-ORF73 (h2Adjusted= 20%, 95% CI= 13−26%), anti-K8.1
(h2Adjusted= 13%, 95% CI= 7–19%) and anti-K10.5 (h2Adjusted=
18%, 95% CI= 11–24%), and for anti-EBNA-1 (h2Adjusted= 20%,
95% CI= 14–27%) and anti-VCA IgG (h2Adjusted= 18%, 95%
CI= 13–25%).
To further investigate the genetic determinants of response to
infection in this population, we conducted GWAS for each
continuous antibody trait combining whole-genome sequencing
and dense genotyping data with imputation to a merged 1000
Genomes phase 3, AGVP32 and UG2G reference panel33.
Stringent sample and variant QC left 4365 individuals with all
phenotypes and ~17M SNPs across autosomal markers and X-
Chromosome for analyses (see ‘Methods’). Homogeneity in the
study population was previously ascertained by principal
components analyses with AGVP populations as a reference
panel11. This model accounted well for population structure and
cryptic relatedness as shown by genomic inflation factor (λ) ~1.0
for all traits (Supplementary Fig. 3). Correcting for multiple
testing, accounting for the lower linkage disequilibrium (LD) in
African populations and using an FDR of 5%, the genome-wide
significance threshold was adjusted to p < 1 × 10−8 11,33. Follow-
ing GWAS of quantitative anti-ORF73, anti-K8.1 and anti-K10.5
IgG levels for 4365 individuals, one locus in association with
K10.5, rs111664408-G (p= 6.64 × 10−09, β, 95% CI=−0.2,−0.29
to −0.15) on chromosome 6, mapped as intergenic between HLA-
B and HLA-C, reached genome-wide significance threshold
(Table 2 and Fig. 4a). In addition, the following variants reached
the standard genome-wide significance threshold (p < 5 × 10−8)
used in European studies which we highlight as they merit being
prioritised for replication in other studies; for K10.5, rs10794590-
T (p= 4.59 × 10−08, β, 95% CI=−0.14, −0.19 to −0.09), an
intergenic variant on chromosome 10 (Table 2 and Fig. 4b) and
for ORF73, rs114429578-T (p= 4.60 × 10−08, β, 95% CI= 0.36,
0.23−0.49) on chromosome 5 mapped in GDNF (Table 2 and
Fig. 4c). Another plausible signal rs510205-G (p= 5.53 × 10−08,
β, 95% CI= 0.21,0.14–0.29) on chromosome 6 mapped in HLA-
DQA1 (Table 2) was also associated with anti-ORF73 IgG. In the
GTEx database, rs10794590 (associated with K10.5 IgG levels)
was associated with the differential expression of ACADSB (p=
2.6 × 10−9) and IKZF5 (p= 1.5 × 10−3) in oesophagus mucosa
and colon tissues. We also found rs510205 (associated with
ORF73 IgG) associated with the differential expression of the
following eight genes, HLA-DQA2, HLA-DQB2, HLA-DQB1,
HLA-DRB1, HLA-DRB6, HLA-DQA1, CYP21A1P and LY6G5B in
whole blood (p < 3.8 × 10−6). Expression data for our other
association signals were unavailable in the GTEx database. We
were unable to refine signals linked to HLA alleles with no
significant associations identified with ORF73 or K10.15 IgG
levels (Supplementary Data 3). We also assessed whether variants
within 23 genetic loci that been previously identified in other
studies with marginal significance as associated with classic KS,
KSHV seropositivity, KSHV viral load, antibody response or
primary effusion lymphoma21,23–25,34–36 were present in this
study and had plausible signals. In this study, 21 out of 31
variants were typed/imputed and were in IL6, IL8RB, IL13, IL4,
IL12A, FCγRIIIA, HLA and IRAK121,23,24,34–36, data for KIR
types22 were unavailable in this study. Despite adequate power
(80%), we did not detect significant associations (p > 0.1) of any
of the previous suggested variants for any of the traits in this
study (Supplementary Table 2).
For EBV infection, GWAS of 3289 individuals, replicated our
previous finding11 rs9272371 in HLA-DQA1 (p= 5.24 × 10−33,
β=−0.37) and identified a distinct secondary signal, rs3129867
in HLA-DRA (pcond= 6.01 × 10−11, β=−0.17) (Supplementary
Table 3). To maximise power, we combined our dataset with 1076
individuals from our pilot study11 and performed GWAS for EBV
response in 4365 individuals (Supplementary Fig. 5). We found
stronger statistical associations for anti-EBNA-1 IgG antibody
responses in the HLA class II region (Table 3 and Fig. 5). The C-
allele at our lead SNP rs9272371 in HLA-DQA1 (p= 3.63 ×
10−44, β=−0.37) was associated with lower antibody levels
(Fig. 5a and Table 3), with the presence of a distinct secondary
signal rs3129867 in HLA-DRA (Fig. 5b and Table 3) with the G
allele associated with lower antibody levels (pcond= 2.78 × 10−11,
β=−0.17). We also identified significant associations for anti-
VCA IgG antibody levels also in the HLA-class II region (Fig. 5c
and Supplementary Fig. 5). The C-allele of the lead SNP
rs71542439, also in HLA-DQA-1, associated with lower antibody
levels (p= 1.15 × 10−12, β=−0.21) (Table 3). To fine map the
associations observed in the HLA region, we tested the presence
or absence of 117 four-digit imputed classical HLA alleles. HLA-
DRB1*15:01 showed the lowest p value for association with EBV
EBNA-1 (p= 4 × 10−4) (Supplementary Data 4) and had very
weak LD with other alleles (r2 < 0.02) (Supplementary Data 5).
We did not replicate HLA-DRB1*0701 (p= 0.86) or HLA-
DQB1*0301 (p= 0.84) alleles (Supplementary Data 4) previously
associated with EBNA-1 IgG in individuals of European
descent13,14. We also did not identify any significant associations
between any classical HLA alleles and VCA IgG levels
(Supplementary Data 4).
Trans-ancestry meta-analysis and fine mapping of anti-EBNA-
1 IgG response. To investigate the portability of findings across
ancestry, we used MANTRA37 to perform a genome-wide trans-
ancestry meta-analysis for anti-EBNA IgG responses, with asso-
ciation summary statistics of 4365 individuals from our Ugandan
GWAS combined with 2162 seropositive individuals from the
1000 Genomes-imputed European ancestry GWAS13, giving a
total of 6527 individuals with ~4.9 million shared SNPs for
analysis. Using a threshold of log10 Bayes Factor (BF) > 638 we
replicated strong evidence of association in the HLA class II
region with lead SNP rs6927022 (log10BF= 44.3) (Supplementary
Fig. 6) previously identified as the lead association SNP in the
European ancestry study13. Our Ugandan lead SNP rs9272371
(log10BF= 43.2) displayed heterogeneity in effect sizes in the two
studies (pQ= 3.56 × 10−8) as identified in our pilot study. To
Table 2 Lead association signals with anti-KSHV IgG antibody levels.
Trait Chr:Pos(b37) Variant Mapped gene(s)a Consequencea EA EAF (%) p β (95% CI)
ORF73 5:37832167 rs114429578 GDNF Intergenic T 3.1 4.60 × 10−08 0.36 (0.23–0.49)
6:32584693 rs510205 HLA-DQA1 Intergenic G 9.4 5.53 × 10−08 0.21 (0.14–0.29)
K10.5 6:31262619 rs111664408 HLA-B/ HLA-C Intergenic G 10.6 6.64 × 10−09 −0.22 (−0.29 to −0.15)
10:124833806 rs10794590 ACADSB Intergenic T 25.7 4.59 × 10−08 −0.14 (−0.19 to −0.09)
EA effect allele, EAF effect allele frequency.
aAnnotated using Ensembl VEP.
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further, refine genetic association signals, using MANTRA results
we generated 99% credible sets most likely to drive association
signals and contain causal variants (or tagging unobserved causal
variants) and compared fine-mapping intervals for each asso-
ciated lead SNP by analysing the variants 500 kb up- and
downstream of the lead SNP in the combined dataset as described
previously39,40. This resulted in three distinct SNPs in the credible
set, rs6927022, rs9272371 and rs9274247 (Supplementary
Table 4) further confirming that rs6927022 does not fully drive
associations in the Ugandan population. No other locus was
found to be in association with anti-EBNA-1 IgG response.
Discussion
In this study, we assessed the seroprevalence of KSHV and EBV
infections along with the burden of co-infections and the influ-
ence of intrinsic, environmental and genetic factors on IgG
antibody responses to infection in a rural African population
cohort of >4000 individuals. Serological assays are useful in
assisting diagnosis, and in improving our understanding of pre-
valence and transmission of infection, in addition to under-
standing virology and host immunity. The presence of antibodies
representing host immune response are commonly used as
diagnostic markers for stage of infection and thus, seroprevalence
is widely used as a measure of the frequency of infections in a
population41. In the GPC, prevalence estimates of KSHV and
EBV are high (>90%) and consistent with previous findings in
Uganda42–46. For KSHV, we found increased antibody ser-
oprevalence and IgG levels in males compared to females as
previously reported30. For EBV, while higher age (>40 years) was
associated with modest decrease in antibody response (OR=
0.64), the background antigenic milieu in this population is dif-
ferent to western populations; it is likely that while antibody levels
increase in childhood, they could decay with time (in adulthood)
as a result of immunomodulation by other factors as observed in
other studies47 or as a result of exposure to other pathogens.
Environmental factors such as co-infection with other pathogens
have been studied and found to influence variation in ser-
oprevalence estimates, and antibody responses associated with
infection45,48. This is consistent with the results presented in this
study, where we found HIV infection to be associated with IgG
antibody response levels to KSHV and EBV infection. While HIV
infection was associated with lower antibody responses to KSHV,
the inverse was observed for EBV antibodies. Similarly, lower
urbanicity and educational attainment were associated with a
decrease in antibody levels to KSHV and increase to EBV (Figs. 2
and 3). This could be due to differential effect of shared epide-
miological risk factors for HIV, EBV and KSHV, and/or as a
result of the mutual inhibition of KSHV and EBV that has been
observed in other studies5,6. Here, we also found that KSHV and
EBV co-infections influence antibody responses to each other,
highlighting the direct or indirect interaction between the two
viruses, which has been previously observed for viral shedding
among Ugandan children and their mothers and also in a
Cameroon KS case control study28,48. As Uganda is also a malaria
endemic area and studies have reported co-infection with P.
falciparum and other parasites as having an influence on antibody
titre45,46,49, it would be useful to also incorporate this in future
study design. While the cohort is indeed rural, a marked variation
in levels of urbanicity across the villages, largely attributable to
differences in economic activity, civil infrastructure, and avail-
ability of educational and healthcare services has been previously
described27. It is interesting that even within a rural setting dif-
ferent levels of ‘urbanicity’ are associated with antibodies sup-
porting broader observations contrasting higher seroprevalence in
rural vs urban settings46,48,50.
In addition to environmental factors described above, host
genetic factors (which might also be influenced by the environ-
ment) can also contribute to phenotypic variation in infectious
disease response traits. To explore the proportion of variance in
antibody responses attributable to the host genetics, we investi-
gated the heritable component of the IgG response to KSHV and
EBV antigens in individuals with genotype data, adjusting for
unmeasured environmental correlation using spatial distances
and similar methodology used in previous studies51. These ana-
lyses show that while KSHV and EBV antibody response traits
were heritable there is overestimation in heritability prior to
accounting for shared environment, which is consistent with our
previous findings in Uganda11. The heritability estimates for
KSHV (h2= 13–19%) are also lower than the reported estimate of
37% in a Mexican-American ancestry cohort52; this deflation in
estimates is similar to what we had previously observed for our
pilot study of EBV in Uganda (h2EBNA-1= 11%) compared to
Mexican-Americans or Europeans (h2EBNA-1= 37–43%)11,12,53,54.
These differences in the GPC compared to other populations
could be attributed to a number of factors including differences in
study/assay design, locus or allelic heterogeneity influencing
traits, not fully adjusting for environmental effects and differences
in gene−environment interactions.
Conducting GWASs for KSHV-associated diseases is challen-
ging as sample sizes are limiting to achieve power for reliable
detection of loci. Prior to this study, GWAS had not been per-
formed for any KSHV phenotype. As previous studies have
shown correlation of IgG levels with the development of
disease55,56, here we used IgG antibody responses as a proxy for
disease progression. While anti-KSHV IgG traits are partly
heritable after accounting for shared environment, despite having
>80% power to detect signals of moderate to large effect sizes (β >
0.15, for MAFs >25%) for all traits, only one genome-wide sig-
nificant locus (p < 1 × 10−8) was identified, the variant
rs111664408 in HLA-B/HLA-C (p= 6.64 × 10−09) on chromo-
some 6 contributing to inter-individual variability in K10.5 IgG
responses. Nonetheless, using the standard genome-wide sig-
nificance threshold (p < 5 × 10−8), two candidate loci associated
with anti-ORF73 and anti-K10.5 IgG response levels were iden-
tified, reflecting the latent stage/history of infection. For anti-
ORF73 IgG, relatively strong associations were in GDNF on
chromosome 5 (rs114429578, p= 4.60 × 10−08) and in HLA-
DQA1 (rs510205, p= 5.53 × 10−08) (Table 2 and Fig. 4). While
Table 3 Loci with significant evidence of association with anti-EBV IgG levels (N= 4365).
Trait Chr:Pos(b37) Variant Nearest genea Consequencea EA EAF (%) p β (95% CI)
EBNA-1 6:32604654 rs9272371 HLA-DQA1 Intron C 26.9 3.63 × 10−44 −0.37 (−0.43 to −0.31)
EBNA-1 6:32404220 rs3129867 HLA-DRA Upstream G 49.2 2.10 × 10−24* −0.25 (−0.30 to −0.20)
VCA 6: 32630257 rs71542439 HLA-DQB1 Intron T 21.1 1.15 × 10−12 −0.21 (−0.27 to −0.15)
EA effect allele, EAF effect allele frequency.
*pcond on lead SNP, β (95% CI)= 2.78 × 10−11, −0.15 (−0.18 to −0.11).
aAnnotated using Ensembl VEP.
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GDNF (encoding glial cell line-derived neurotrophic factor) has
not been previously implicated in KSHV pathogenesis, it has been
reported to be critical in the maintenance of latency for Herpes-
simplex viruses infections57. The HLA class I and II regions,
however, have been reported to play a role in the pathogenesis of
KSHV and KS; nevertheless, previous genetic association studies
have failed to identify convincing and reproducible associations at
these loci23,25. Activation of CD4+ T cells is particularly
important for anti-KSHV immunity and in vitro studies have
shown the CD4+ T cells can inhibit viral replication in KSHV-
infected tonsillar B cells58,59. Like EBV, KSHV has evolved stra-
tegies to evade immune detection, including negatively regulating
the process by which HLA class II molecules present antigens to
CD4+ T cells, thereby promoting its survival. Recently, ORF73
and v-IRF3 (K10.5) have been reported to inhibit MHC class II
peptide presentation by blocking the transcription of the class II
transactivator (CIITA), a master regulator of class II expres-
sion60–62. These findings suggest that variation in genes that play
a role in modulating the immune response, particularly, T-cell
immunity could contribute to inter-individual differences in anti-
ORF73 and anti-K10.5 IgG levels to control KSHV viral infection,
and thus, merit prioritisation in further replication studies in
other populations.
For EBV infection, we and others have previously confirmed
the presence of variants in the HLA Class II region driving
associations for EBV EBNA-1 antibody response in different
populations11–14; here we replicated these findings in HLA-DQA1
(rs9272371, p= 3.63 × 10−44) (Fig. 5a) and identified an addi-
tional distinct variant (rs3129867, pcond= 2.78 × 10−11) in HLA-
DRA (Fig. 5b) contributing to IgG levels in Uganda that was not
identified as distinct in our initial pilot study11. We also identified
an association at rs28394498 (p= 1.15 × 10−12) in HLA-DQA1
with anti-VCA IgG levels (Fig. 5c). We attempted to fine map the
HLA region; HLA-DRB1*1501 present in 1.1% of individuals in
this study was the most significant association signal (p= 4.7 ×
10−4, β= 0.42) for EBNA-1 IgG. Interestingly, however, it did
not explain our lead GWAS signal in HLA-DQA1. We also did
not replicate HLA alleles DRB1*0701 and DQB1*0301 previously
associated with EBNA-1 IgG levels in two GWASs consisting
individuals of European descent13,14. Both studies, however,
retained the significance of their lead GWAS SNPs in the HLA
region after adjusting for the effect of the lead HLA alleles
(residual p < 2.6 × 10−11)13,14, and thus, could not fully explain
the lead GWAS signal, which is consistent with our findings. This
suggests the relevance of additional alleles or a non-HLA effect
that did not reach significance or is absent in our study. It is also
likely that allelic/haplotypic heterogeneity in Africans vs Eur-
opeans, an expression modulating effect or HLA imputation
errors play a role particularly, given the limited representation of
Africans in the multi-ethnic reference panel63. Trans-ancestry
meta-analysis of European and African individuals in the HLA
class II region confirmed distinct association signals in the two
populations. As with our previous findings, rs9272371 and
rs6927022 are likely to be distinct variants in the HLA class II
region, with a single signal in Europeans (rs6927022) and a signal
mostly driven by rs9272371 in Uganda (Supplementary Table 4).
Thus, future studies should aim to further refine signals in larger
sample sizes in individuals of African descent and using HLA
panels based on African data which are currently in development.
In summary, we characterise systematic differences in >4000
individuals with evidence of infection by KSHV and EBV in
Uganda and identify determinants of response to infection. The
availability of data on environmental covariates such as co-
infection with other pathogens allowed us to capture genetic
variation independently of the environment. Co-infection was
indeed a strong predictor of inter-individual variability in
antibody responses and highlighted significant and complex
interactions between EBV and KSHV. Despite similar heritability
and power for KSHV and EBV traits, it was interesting to observe
less genome-wide statistically significant associations for the
former; this suggests differences in underlying genetic archi-
tectures between the traits. It is possible that variants with very
small effect sizes or low-frequency variants (i.e. EAF <0.5%)
influence inter-individual variability in KSHV immune responses;
however, this study is under-powered to detect low-frequency
variants with small effect sizes and neither the genetic data nor
the tools used here are optimal for accurate rare variant detection.
As sub-Saharan Africa sustains such high transmission compared
to the rest of the world, these insights are useful to better
understand fundamental biological processes of gamma-
herpesvirus infection and their epidemiological characteristics
to inform appropriate therapeutic interventions and to control
their transmission. Lastly, given there are no equivalent datasets
from African populations, summary statistics derived from this
study are a useful resource for others to use.
Methods
Ethics approval and consent. Informed consent was obtained from all partici-
pants either in conjunction with parental/guardian consent for under 18-year-olds
with signature, or a thumb print if the individual was unable to write. The study
was approved by the Uganda Virus Research Institute, Research Ethics committee
(UVRI-REC) (Ref. GC/127/10/10/25), the Uganda National Council for Science
and Technology (UNCST) (Ref. HS 870), and the UK National Research Ethics
Service, Research Ethics Committee (UK NRES REC) (Ref. 11/H0305/5).
Sample selection and collection. The GPC is a population-based cohort in Kya-
mulibwa, rural south-west Uganda, consisting of 25 neighbouring villages inhabited
mainly by farmers who grow subsistence crop, cultivate coffee for trade and also raise
livestock26,64. Households are scattered with some concentrated in the trading centres.
Villages were categorised by urbanicity quartiles to reflect shared socio-demographic
and ‘urban’ characteristics based on seven components: population size, economic
activity, built environment, communication services, educational facilities, health
services, and diversity as previously described elsewhere27. Blood samples from 7000
GPC study participants, representing 11 self-reported ethnolinguistic groups, were
collected during medical survey sampling conducted in the study area between 2010
and 201126. Details of sexual behaviour, medical, socio-demographic and geographic
factors were also recorded. Serum was tested for HIV-1, Hepatis B (HBV) and
Hepatitis C (HCV) infections and the remainder was stored at −80 °C in freezers in
Entebbe prior to further serological testing.
Serology and quality control of phenotypic data. We quantified MFI to measure
the levels of serum IgG antibodies to the KSHV encoded antigens ORF73, K8.1 and
K10.5; and to the EBV encoded EBNA-1 VCA and EAD covalently bound to
fluorescent magnetic beads and read on a multiplexed platform28. Pairwise-
correlation between phenotypes was tested for using Pearson’s correlation in R. For
each virus, seropositivity was defined as having antibody level to any antigen tested
above a prespecified cut-off, as previously described29. Of the original ~7000 people
genotyped, we were able to link phenotype results from 4365 people (mean age ±
SD= 34 ± 18 years, 54% female) from samples collected from the GPC in 2011.
Statistical analysis of quantitative antibody levels. To investigate factors
influencing IgG antibody response to KSHV and EBV infections, categorical out-
come variables for antibody serostatus (i.e. positive/negative)29 and continuous
variables for antibody levels (log10 transformed MFI) were generated and analysed
with potential risk factors. The following variables were considered to be possible
risk factors or confounders: sex, age (years) or age group (categorised as 13–18,
19−35 or ≥40 years), ethnic group (Baganda or other), education level attained
(none/primary, junior secondary, senior secondary or tertiary), village urbanicity
quartile (1−4 with 4 being most urban) based on shared socio-demographic or
‘urban’ characteristics as previously described27. HIV infection, HBV infection,
HCV infection, and anti-KSHV serostatus and log10 antibody levels (anti-K8.1,
anti- ORF73 and anti-K10.5), or anti-EBV antibody serostatus and antibody levels
(anti-EBNA-1, anti-VCA and anti-EAD log10 MFI). Multivariate logistic or linear
regression models were fitted to examine variables predictive of antibody levels. All
variables in the model were independent of each other except for urbanicity
quartile and education (χ2, p < 0.001) and age and education (χ2, p < 0.001);
nonetheless, we do not identify significant collinearity in our models as variance
inflation factors were all close to 1. A multiple testing p value of <0.006 was used to
determine statistical significance.
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Genetic data curation and quality control. Of the 7000 GPC samples, 5000 were
densely genotyped on the Illumina HumanOmni 2.5M BeadChip array and we then
imputed additional variants into the genotype chip dataset using a merged 1000
Genomes phase 3 65, African genome variation project32 and UG2G (Uganda 2000
Genomes) reference panel in IMPUTE266. Whole-genome sequencing was performed
on 2000 samples with 100 base paired end sequencing at 4× coverage on the Illumina
HiSeq 2000 platform following the manufacturer’s protocol. Stringent variant and
sample quality control (QC) filtering was performed. Low-quality variants that
mapped to multiple regions within the human genome or did not map to any region,
and duplicate variants genotyped on the chip were removed. We excluded samples
with a call rate <97% and heterozygosity >3 SD from the mean, discordant genetic sex
and reported sex, and sites deviating from Hardy−Weinberg equilibrium (p < 10−8).
Following imputation, we only included high-quality sites (info score > 0.3 and r2 >
0.6) with minor allele frequency (MAF) ≥ 0.5%. We also removed samples without
matching phenotype and genotype or sequence data. Of the merged datasets,
343 samples had overlapping genotype and sequence variant calls for which a final
concordance of 98% was achieved for all SNPs. The merged datasets post QC filtering
resulted in 4365 samples with KSHV and EBV phenotypes and ~17M SNPs across
the autosomes and X-chromosome for analyses. For EBV analyses we first performed
primary GWAS of 3289 unique individuals and then in 4365 individuals i.e. in
combination with 1076 overlapping samples present in our pilot study11.
HLA region imputation. Human leucocyte antigen alleles were imputed using
genotype data available from across the extended MHC region only (chromosome 6
base pair positions 25,500,000−34,000,000 in genome build 37) and SNP stranded-
ness was checked with the HLA*IMP front-end software67. HLA genotypes of 117
alleles (AF > 1%), at 11 loci were imputed with HLA*IMP:0263 using the standard
HLA*IMP:02 multi-ethnic reference graphs, representing ~800 reference individuals
for HLA-DRB3/4/5 and >6000 reference individuals for all other loci.
Heritability of antibody response traits in the GPC. Narrow-sense heritability
(h2) for anti-EBNA-1 IgG, anti-VCA IgG, anti-ORF73 IgG, anti-K8.1 IgG and anti-
K10.5 IgG traits were estimated using a linear mixed model (LMM) in FaST-LMM
with two random effects, one based on genetic effects and the other on environ-
mental effects using spatial location31 recorded as Global Position System (GPS)
coordinates as a proxy for environmental effects.
Genome-wide association analyses. The statistical power to identify genetic
variants of genome-wide significance and with different effect sizes given the
sample size was estimated using QUANTO software (http://biostats.usc.edu/
software). We conducted analyses for all quantitative antibody traits for KSHV
(N= 4365) and EBV (N= 3289 and N= 4365 (including overlapping samples
from pilot study) by first applying a multivariable linear regression model adjusting
for significant covariates in R. Residuals of MFI values used for analyses were then
transformed using inverse, rank-based normalisation in R to ensure a standard
normal distribution for the phenotypes and confirmed by visualisation. To control
for cryptic relatedness and population structure within the GPC, the GWAS of
transformed phenotypes was performed using the standard mixed model approach
in GEMMA68. A kinship matrix to define pairwise genetic relatedness among
individuals was generated using pooled imputed genotypes and sequence data for
all autosomes and X-chromosome using the k= 1 option in GEMMA. The data
were LD-pruned (r2= 0.2) using dosages and an MAF threshold of 1% was applied.
Environmental correlation using GPS data as a proxy, genotyping or sequencing
method were also adjusted for as additional covariates during analysis in GEMMA.
To identify distinct SNPs, conditional analysis was performed in GEMMA. Each
SNP within 1MB of the lead association SNP was conditioned. If any SNP was
statistically significant, it was added stepwise onto the mixed model and analysed
jointly; this was done until no SNPs with p < 5 × 10−9 11,33 remained. All SNPs
remaining statistically significant were considered distinct association signals. To
functionally annotate our most significant associations, we used the Ensembl
Variant Effect Predictor (VEP)69 and the gene/tissue expression database (GTEx:
https://gtexportal.org) V8 release to access data on expression quantitative trait loci
(eQTLs) from tissues. To test associations between imputed HLA allele and amino
acid dosages and phenotypes, we performed linear regression of transformed
phenotypes in GEMMA as performed in the SNP-based GWAS for that phenotype.
Trans-ancestry meta-analysis and fine mapping. MANTRA was used to per-
form a genome-wide trans-ethnic meta-analysis for anti-EBNA IgG responses with
association summary statistics of 4365 individuals from our Ugandan GWAS
combined with publicly available data of 1000 Genomes-imputed European
ancestry GWAS from 2162 seropositive individuals, giving a total of 6527 indivi-
duals with ~4.6 million shared SNPs for analysis. The MANTRA approach
leverages differences in LD structures across populations to account for differences
in genetic architecture and accommodates heterogeneity of allelic effects between
distantly related populations within a Bayesian partition framework37. To deter-
mine statistical significance, we use a threshold of log10 Bayes Factor (BF) > 6 which
is comparable to a p < 5 × 10−8, previously determined by Wang et al.38. Hetero-
geneity of allelic effect sizes was calculated using Cochran’s Q-test for heterogeneity
in METAL70. Using MANTRA results we generated 99% credible sets most likely
to drive association signals and contain causal variants (or tagging unobserved
causal variants) and compared fine-mapping intervals for each associated lead SNP
by analysing the variants 500 kb up- and downstream of the lead SNP in the
Ugandan and combined Ugandan+ European datasets. For this, posterior prob-
abilities were calculated for SNPs and then ranked in decreasing order according to
BF, proceeding down the rank until the cumulative posterior probability exceeded
99%39,40. All SNPs ≥ 0.99 were included in the credible sets.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Summary statistics are available on the NHGRI-EBI GWAS Catalogue https://www.ebi.
ac.uk/gwas/downloads/summary-statistics under accession codes: GCST90000522,
GCST90000523, GCST90000524, GCST90000525, GCST90000526.
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